Moses Vaporization: Is Use of Moses 2.0 in Holmium Laser Ablation of the Prostate More Efficient

Launched by UNIVERSITY OF KANSAS MEDICAL CENTER · Jul 26, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new technique called Moses 2.0, which is used during a procedure known as holmium laser vaporization to treat an enlarged prostate, a condition that can cause bothersome urinary symptoms in men. The main goal is to see if using Moses 2.0 makes the procedure more effective by reducing tissue damage (char), improving visibility for the doctor, and controlling bleeding better during the treatment.

To participate in this trial, men aged 18 and older with significant urinary symptoms who are considering surgery may be eligible, as long as their prostate is 60 grams or smaller. However, individuals who are currently taking blood-thinning medications (except for a low dose of aspirin), have certain bleeding disorders, or have specific diagnoses like prostate cancer or urinary retention will not qualify. Participants can expect to be closely monitored throughout the study, and their experiences will help researchers understand if this new technique can improve treatment outcomes for men with prostate issues.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients \> 18 years of age
• • Patients with bothersome lower urinary tract symptoms who opt for surgical management
• • Prostate size 60g or less
• Exclusion Criteria:
• • Current use of anticoagulation or antiplatelet agent Aspirin 81 use is okay and can be continued through the study
• • Bleeding diathesis
• • AUA symptom score \< 9
• • Current urinary retention
• • Known diagnosis of prostate cancer
• • Known diagnosis of neurogenic bladder